MedTrace Logo

Bioinformation Therapy for Lung Cancer

NCT03239171 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2019-01-25

No results posted yet for this study

Summary

The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable lung cancer.

Conditions

  • Small-cell Lung Cancer

Interventions

DEVICE

Cancer ablation

Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.

DRUG

Life information rehabilitation therapy

Each treatment: one bottle solution each day, consecutive 3 months, oral administration

Sponsors & Collaborators

  • Shengxin Biotechnology Institute, Beijing

    collaborator OTHER

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-02
Primary Completion
2018-09-02
Completion
2018-09-02

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03239171 on ClinicalTrials.gov